Active	Status	Sponsor type	Region	Phase	Filter
26 Active 0 Inactive 26 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Alva, Elizabeth D
CaboMain, NCT05135975: A Study of Cabozantinib As a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors	Recruiting	2	86	US	Cabozantinib	Nationwide Children's Hospital, Exelixis	Neuroblastoma, Sarcoma	07/25	12/29
PEDS-PLAN, NCT02559778: Pediatric Precision Laboratory Advanced Neuroblastoma Therapy	Recruiting	2	500	Canada, US	Ceritinib, Zykadia, dasatinib, Sprycel, sorafenib, Nexavar, vorinostat, ZOLINZA, DFMO, Eflornithine, α-difluoromethylornithine	Giselle Sholler, Dell, Inc., Beat NB Cancer Foundation, K C Pharmaceuticals Inc., Team Parker for Life	Neuroblastoma	09/30	09/35
CA209-9WW, NCT03628209: Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma	Active, not recruiting	1/2	21	US	Nivolumab, Opdivo®, Azacitidine, Vidaza®, Post Treatment Surgery, Standard of Care, Resection of disease	H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb	Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma	12/24	12/25
Tate, Bridget
PEDS-PLAN, NCT02559778: Pediatric Precision Laboratory Advanced Neuroblastoma Therapy	Recruiting	2	500	Canada, US	Ceritinib, Zykadia, dasatinib, Sprycel, sorafenib, Nexavar, vorinostat, ZOLINZA, DFMO, Eflornithine, α-difluoromethylornithine	Giselle Sholler, Dell, Inc., Beat NB Cancer Foundation, K C Pharmaceuticals Inc., Team Parker for Life	Neuroblastoma	09/30	09/35
NCT06679582: Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age with Relapsed/Refractory CBFA2T3::GLIS2 AML	Recruiting	1/2	24	US	Luveltamab tazevibulin, STRO-002, Luvelta	Sutro Biopharma, Inc., Children's Oncology Group (COG), Innovative Therapies For Children with Cancer Consortium	Acute Myeloid Leukemia (AML)	12/28	03/29